Summary of Huadong Medicine Conference Call Company Overview - Huadong Medicine is a leading enterprise in the pharmaceutical industry, with a strong channel advantage, particularly in the metabolic and autoimmune fields. The company was established in 1993 and listed on the Shenzhen Stock Exchange in 2000. Its business encompasses pharmaceutical manufacturing, commercial operations, and medical aesthetics, with pharmaceutical manufacturing being the largest segment. In 2024, the company expects industrial revenue of approximately 14 billion yuan, commercial revenue of about 28 billion yuan, and medical aesthetics revenue of around 2 billion yuan [3][4][7]. Financial Performance - In 2024, Huadong Medicine's total revenue is projected to exceed 40 billion yuan, representing a year-on-year growth of 3%. The net profit attributable to shareholders is expected to grow by over 20%, benefiting from business transformation and the clearance of negative factors [2][4]. Innovation and Product Pipeline - The company is actively developing innovative drugs in the fields of diabetes, weight loss, autoimmune diseases, and oncology. The first domestic generic version of Liraglutide has been approved, with Semaglutide and other products expected to be approved soon. The company is also developing multi-target GLP-1 products such as HDM1,002 and HDM1,005, which are anticipated to quickly capture market share [2][6][14]. Commercial Operations - The commercial segment, primarily located in Zhejiang Province, is expected to generate over 28 billion yuan in revenue in 2024, a 3% increase year-on-year. The company has restored stable profitability through innovative development and has a competitive advantage in market access and network coverage, which synergizes well with its industrial operations [2][7][23]. Medical Aesthetics - The medical aesthetics segment has seen significant success, with the "Girl Needle" product achieving over 1 billion yuan in sales. The company also offers hyaluronic acid and energy source devices, with expectations for double-digit growth in 2025. The acquisition of UK-based Sinclair has facilitated global expansion [8][9][20]. Risks and Challenges - Key risks include potential delays in innovative product development, intensified market competition, and lower-than-expected sales of core products. These factors could impact future performance and require ongoing monitoring and strategic adjustments [10]. ADC and Oncology Developments - Huadong Medicine has made substantial innovations in the ADC (Antibody-Drug Conjugate) field, with significant products like HDM1,022 and HDM1,005 targeting advanced malignancies. The company is also collaborating with other firms to develop CAR-T therapies, which are expected to contribute to revenue growth [15][16][17]. Industrial Microbiology - The industrial microbiology segment has maintained rapid growth of 30%-40% in recent years, contributing significantly to revenue. The company has over 40 years of experience in this field, with leading subsidiaries in the industry. Industrial microbiology revenue is expected to exceed 700 million yuan in 2024, reflecting a 40% year-on-year increase [21][22]. Valuation and Future Outlook - The current market capitalization of Huadong Medicine is over 70 billion yuan, with projected profits for 2025 estimated between 3.9 billion and 4 billion yuan, resulting in a price-to-earnings ratio of less than 20 times. This valuation is considered low given the company's innovative transformation and traditional channel advantages. The company has multiple core innovation pipelines in autoimmune, endocrine, and oncology fields, which are expected to enhance market recognition through potential overseas licensing agreements [24].

Group 1 - The report indicates that the North Exchange has accelerated its IPO approvals, with a total of 9 companies approved from January to June 2025, suggesting an increase in listing pace as companies finalize their 2024 annual reports [3][11]. - The average number of effective online subscription accounts reached 460,100, with an average of 475.2 billion yuan in frozen funds during the same period, reflecting heightened market activity [3][12]. - The average fundraising amount per company in the North Exchange for the first half of 2025 was 396 million yuan, representing a 94.55% increase compared to 2024, indicating a trend towards larger fundraising efforts [3][20]. Group 2 - The North Exchange's overall PE ratio decreased to 50.12X, with the North 50 Index closing at 1,382.74 points, down 0.71% for the week, highlighting a volatile market environment [4][30][32]. - The report notes that 143 companies in the North Exchange have a PE ratio exceeding 45X, with 71 companies exceeding 105X, indicating a significant portion of the market is highly valued [4][35]. - The average maximum online subscription limit was 9.81 million yuan, with a notable increase to 16.13 million yuan in the first half of 2025, suggesting improved investor capacity for participation [3][24]. Group 3 - The report highlights that from January 1, 2024, to June 13, 2025, the average subscription rate for companies raising over 200 million yuan was 0.14%, compared to 0.06% for those raising less, indicating a correlation between fundraising size and subscription success [3][17]. - The average subscription threshold for 100 shares was 1.5827 million yuan, which increased to 1.8591 million yuan in the first half of 2025, reflecting rising entry costs for investors [3][27]. - The report emphasizes the importance of focusing on companies with reasonable valuations and strong performance potential, particularly those that align with new industrial and technological trends [4][44].

Core Viewpoint - Sichuan Province has introduced measures to promote the development of the pharmaceutical and health industry, focusing on six specific sectors: nuclear medicine, biomedicine, medical devices, sports, modern traditional Chinese medicine, and medical beauty [1][2] Group 1: Support for Innovation and Research - The measures support the establishment of national-level research platforms, including key laboratories for biotherapy and oral disease prevention, as well as major scientific infrastructure for translational medicine [1] - Emphasis is placed on collaboration between academic and research institutions and quality enterprises in the industry chain, particularly in areas like malignant tumors and emerging infectious diseases [1] - The initiative aims to develop innovative drug projects in fields such as cell therapy, gene therapy, synthetic biology, and brain science, along with a focus on creating a key research and development catalog for innovative drugs [1] Group 2: Financial Support and Incentives - The measures integrate resources to provide financial support for key industry projects, including a program that offers up to 40% of the total contract amount for project funding, with a maximum of 20 million yuan per project [2] - Specific subsidies are outlined for nuclear medicine projects, with a maximum subsidy of 20% of the project investment and a cap of 2 million yuan, while research projects can receive up to 30% of their R&D investment, capped at 1 million yuan [2] - Additional financial incentives include 40 million yuan annually for the top five cities in sports industry development, and up to 200,000 yuan for outdoor sports base construction projects [2] Group 3: Streamlined Processes - The measures establish a "key project service team" for pharmaceuticals and medical devices, ensuring that innovative drugs complete network review within 15 working days [2]

Group 1 - The core viewpoint of the article is the launch of the "Beijing Fashion Consumption Expansion Special Action Plan," which includes 21 measures across six areas to enhance fashion consumption and improve consumer experience in Beijing [1][2][3][4][5] Group 2 - The plan aims to establish Beijing as a global launch center for fashion brands, encouraging the establishment of flagship stores and innovation concept stores by global premium brands [2] - It promotes collaboration between traditional brands and well-known IPs to revitalize local brands and enhance their market presence [2] - The initiative includes hosting high-profile sports events to stimulate the event economy and enhance market operations [3] Group 3 - The plan emphasizes the integration of new technologies such as virtual reality, artificial intelligence, and the metaverse to create innovative shopping experiences like VR shopping and AR fitting [4] - It encourages the development of personalized services in the beauty and health industry, leveraging advancements in medical aesthetics [4] Group 4 - The plan calls for strengthening intellectual property rights protection and encourages investment in fashion design, with potential tax benefits for qualifying design expenses [5]

Group 1 - The core viewpoint of the article emphasizes the support for furniture and home furnishing enterprises in Beijing to transform and develop whole-house customization businesses [1] - The Beijing Municipal Bureau of Commerce and other departments have issued a plan to expand fashion consumption, focusing on leveraging smart manufacturing advantages [1] - The plan encourages the application of new technologies such as virtual reality, artificial intelligence, and the metaverse to innovate fashion consumption scenarios [1] Group 2 - The initiative aims to enhance product aesthetics and functional integration, optimizing human-computer interaction experiences [1] - There is a specific encouragement for the development of smart home products and the expansion of medical beauty projects and personalized service scenarios [1] - The plan also promotes the use of technology to empower tourism and commercial services, enhancing service levels in cultural and tourism venues [1]

6月6日，继北证50指数，北交所官方发布北证专精特新指数。对此，北研君认为主要把握三个重点 （1）了解新指数的编制情况；（2）专精特新指数最新成分股和北证50指数有哪些异同；（3）复盘北 证50指数，新指数的出现会对市场造成哪些影响，对交易有什么实质性指导意义。三点中尤其是第三 点，最为重要，下面北研君为大家逐一解答： 1、北证专精特新指数的编制情况？ 对比北证50指数和北证专精特新指数，大部分内容是相同的，主要区别体现在（1）选样方面北证专精 特新指数选样条件为样本空间内的证券按照过去六个月的日均成交金额由高到低排名， 剔除排名后30% 的证券 ，北证50则是剔除排名后20%的证券；（2）选样方面专精特新指数新增限制条件为 必须在专精 特新"小巨人"企业中进行筛选 ，即选取其中专精特新"小巨人"作为待选样本，这条规则使的一些非专精 特新企业无法纳入该指数，北证50指数则无此约束，目前北交所已上市的266家公司中国家级专精特 新"小巨人"为141家，如果算上省级的专精特新数量为192家，占比达72.18%。（3）样本股调整方面北 证专精特新指数为 每半年调整一次，每次调整数量一般不超过20% ，而北证50指数 ...

2025 年 06 月 08 日 北证专精特新（899601）：小而精， 特色更鲜明的优质投资标的 ——北交所发布北证专精特新指数点评 证券分析师 刘靖 A0230512070005 liujing@swsresearch.com 研究支持 吕靖华 A0230124070002 lvjh@swsresearch.com 联系人 吕靖华 (8621)23297818× lvjh@swsresearch.com 策 略 研 究 证 本研究报告仅通过邮件提供给 中庚基金 使用。1 请务必仔细阅读正文之后的各项信息披露与声明 A 股 策 资料来源：Wind，申万宏源研究；截至 2025/6/6 资料来源：Wind，申万宏源研究；截至 2025/6/6 略 券 研 究 报 告 ⚫ 事件：2025 年 6 月 6 日，北交所公告将于 2025 年 6 月 30 日正式发布北证专精特新指 数，经流动性筛选后，北证专精特新指数将从符合条件的北交所专精特新"小巨人"上市 公司中选取市值最大的 50 只作为指数样本，为市场提供多维度投资标的和业绩基准。 ⚫ 北证专精特新聚焦小巨人、特色更鲜明，编制规则采用半年度调仓、调整数量不超 ...

Group 1 - The North Exchange will officially launch the North Specialized and Innovative Index on June 30, 2025, which will provide multi-dimensional investment targets and performance benchmarks [1][9] - The index will consist of the 50 largest "little giant" companies listed on the North Exchange, reflecting the overall performance of specialized and innovative companies [1][9] - As of June 6, 2025, there are 146 national-level specialized and innovative "little giant" companies listed on the North Exchange, accounting for 54.89% of the total [1][14][17] Group 2 - In 2024, the average revenue of national-level specialized and innovative companies on the North Exchange was 613 million yuan, while non-national-level companies had an average revenue of 768 million yuan, with year-on-year changes of -6.88% and +2.40% respectively [1][15] - The average net profit attributable to shareholders for national-level specialized and innovative companies was 47.83 million yuan, compared to 35.16 million yuan for non-national-level companies, with year-on-year changes of -20.72% and -24.34% respectively [1][15] - The gross profit margin for national-level specialized and innovative companies was 25.11%, while for non-national-level companies it was 21.83% [21][24] Group 3 - The North Exchange's A-shares had an average daily trading volume of 24.83 billion yuan, a decrease of 2.38% from the previous week, with a turnover rate of 6.18% [2][30] - The North 50 Index closed at 1427.06 points, with a week-on-week increase of 1.30% and a PE ratio of 74.42X [2][31][35] - The overall PE ratio for North Exchange A-shares increased to 50.21X, with 144 companies having a PE ratio exceeding 45X, accounting for 54.55% [2][33][38] Group 4 - The five major industries on the North Exchange, including high-end equipment, information technology, new chemical materials, consumer services, and biomedicine, have TTM PE ratios of 40.68X, 101.69X, 42.50X, 56.05X, and 51.53X respectively [2][37][39] - The North Exchange focuses on serving innovative small and medium-sized enterprises, particularly in advanced manufacturing and modern service industries, to promote high-quality economic development [1][14]

Group 1: Company Overview and Strategy - The company focuses on real estate development and sales, with a strong presence in the Yangtze River Delta region, adhering to a "long-termism" philosophy and a strategy of "steady operation and progress" [2][3] - The company maintains a "low debt, high return" operational strategy while advancing its dual business model in real estate and medical aesthetics [2][3] Group 2: Real Estate Business Performance - The real estate sector remains under pressure, but market sales data is stabilizing; the company benefits from ample quality land reserves and low land costs, with a total land reserve of over 1.7 million square meters [3] - Key projects like Binjiang Yayuan and Rongjin Ruifu are performing well, with strong sales and high profitability [3][4] Group 3: Future Development Plans in Real Estate - The company plans to continue its high-profit and positive cash flow real estate projects, with new projects set to launch in advantageous areas in the second half of the year [4] - The company will focus on upgrading and launching premium projects while maintaining a stable pricing system [4] Group 4: Medical Aesthetics Business Performance - The company has established six medical aesthetics institutions, creating a distribution pattern across six cities, and is committed to compliance and quality management [5][6] - The revenue and profit from the medical aesthetics sector are gradually increasing, with expectations for significant growth in revenue share by 2026 as new institutions open in the Yangtze River Delta [6] Group 5: Market Conditions and Future Outlook for Medical Aesthetics - The medical aesthetics market is experiencing a slowdown, with increased concentration and the exit of smaller players; however, the company focuses on high-end clientele and maintains a stable pricing strategy [7][8] - The company aims to expand its medical aesthetics business while exploring new industries and opportunities for sustainable growth [8]

Core Viewpoint - The recent announcement by the State Administration for Market Regulation (SAMR) regarding typical cases of illegal advertising highlights the ongoing issues of false advertising and exaggerated claims in the medical and pharmaceutical sectors, necessitating stricter regulatory measures to protect consumer rights and public health [1][3][5]. Regulatory Actions - In April 2023, SAMR issued a notice focusing on five key areas, including medical, pharmaceutical, health food, special medical purpose formula food, and medical device advertising, to enhance market order and consumer protection [1][5]. - The release of the "Medical Advertising Regulatory Work Guidelines" in May 2023 marks a new phase in the regulation of medical advertising, providing clear legal boundaries and institutional support for patient rights and market order [2][6]. Case Examples - Among the ten typical cases of illegal advertising published, six involved the pharmaceutical sector, including a case where a company was fined 194,000 yuan for advertising unapproved medical devices [3][4]. - Other cases included misleading advertisements for medical services and products claiming disease prevention or treatment capabilities, resulting in fines totaling 1.4 million yuan across various cases [3][4]. Enforcement Statistics - As of April 2023, nationwide efforts have led to the investigation of 11,459 illegal advertising cases, with fines totaling approximately 88.31 million yuan [5][6]. - Specific regions, such as Anhui, reported 1,458 leads on illegal medical advertising and 452 cases of violations, demonstrating the effectiveness of local regulatory actions [5]. Future Directions - Experts suggest enhancing the regulatory framework by refining advertising review standards and establishing comprehensive monitoring mechanisms [7]. - The introduction of technology-driven solutions, such as an intelligent monitoring system for medical advertisements, is recommended to improve compliance and enforcement [7].